Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) announced that its CMO, Amy Summy, was named on the 2021 Forbes CMO Next list for her leadership during the COVID-19 pandemic. Her contributions include spearheading a successful rebranding strategy and launching the Pixel by Labcorp™ at-home testing kits. Recognized for innovation and impact in healthcare, Summy emphasized the role of Labcorp employees in fighting COVID-19. The company reported a revenue of $14 billion in FY2020 and aims to improve patient outcomes across various diseases.
Labcorp (NYSE: LH) reported a strong performance for Q4 and full year 2020, with revenues of $4.49 billion in Q4, a 52% increase year-over-year, driven by COVID-19 testing and a growing base diagnostics business. Net earnings rose to $938.3 million, or $9.54 per diluted share. For 2021, the company projects revenue growth of 1% to 4% and expects a 50% decline in COVID-19 testing revenues. Labcorp emphasized its commitment to science and innovation and anticipates free cash flow between $1.70 billion and $1.90 billion.
Labcorp (NYSE: LH) has announced the appointments of Dr. Prasanth Reddy as senior vice president and enterprise oncology head, and Dr. Robert Phillips as vice president and head of enterprise oncology science. This move aims to strengthen Labcorp's capabilities in cancer diagnosis, treatment, and drug development. Dr. Reddy and Dr. Phillips bring extensive experience in oncology and drug-linked diagnostics from their previous positions at Foundation Medicine and Daiichi-Sankyo, respectively. Labcorp continues to expand its leadership in advancing innovative cancer solutions.
Summary not available.
Labcorp (NYSE: LH) has appointed Dr. Deborah Ann Sesok-Pizzini as its new Chief Medical Officer of Labcorp Diagnostics, effective January 11, 2021, following Dr. Dot Adcock's retirement in April 2021. Dr. Sesok-Pizzini brings over 20 years of healthcare experience, having previously served in various leadership roles at The Children's Hospital of Philadelphia and as a professor at the University of Pennsylvania. Dr. Brian Caveney expressed enthusiasm about her contributions to the team.
Labcorp (NYSE: LH) will announce its fourth quarter and full year 2020 financial results on Feb. 11, 2021, prior to market opening. A conference call will follow at 9:00 a.m. ET to discuss the results. Last year, Labcorp reported revenues of $11.5 billion. The investor relations website will provide the earnings release and additional information. An audio replay of the call will be available until Feb. 25, 2021. The company advises stakeholders to consider forward-looking statements cautiously due to various market risks.
Labcorp (NYSE: LH) has secured a contract with the CDC to conduct genomic sequencing for SARS-CoV-2, supporting a comprehensive genomic survey across the U.S. The initiative aims to enhance national surveillance, identify new variants, and refine public health responses. Labcorp will process random de-identified samples that test positive for the virus, contributing to the CDC's goal of increasing genomic sequencing capacity. This collaboration is set to double the weekly genomic sample sequencing rate, as stated by Labcorp's Chief Scientific Officer, Dr. Marcia Eisenberg.
Labcorp (NYSE: LH) announced that Dr. Brian Caveney, chief medical officer, was recognized by Modern Healthcare as one of the 100 most influential people in healthcare for 2020. This accolade highlights Dr. Caveney's leadership during the COVID-19 pandemic, including the launch of the first commercial COVID-19 PCR test. He praised Labcorp's teams for their dedication and innovation in addressing the crisis. The full ranking is available in the December issue of Modern Healthcare. Labcorp reported $11.5 billion in revenue for FY2019, providing critical insights to improve health worldwide.
Labcorp (NYSE: LH) announced participation in a virtual fireside chat at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 8:20 a.m. (EST). The event will provide insights from the executive management team and will be available via live webcast on their website. With reported revenue of $11.5 billion in FY2019, Labcorp continues to leverage its diagnostics and drug development capabilities across over 100 countries, aiming to enhance healthcare decisions globally.
Labcorp (NYSE: LH) announced that its Pixel by Labcorp™ At-Home COVID-19 Collection Kit is now available through Walgreens Find Care®. This digital health platform assists users in accessing COVID-19 testing services easily. Patients can initiate testing by completing a survey, and kits are shipped for self-collection, with results available online. Labcorp aims to provide convenient health services and enhance access to testing amid the COVID-19 pandemic, which is crucial for informed health decisions.